| Test Name: |
|
EBV Qualitative by PCR, BAL
|
|
|
|
|
|
|
| Test Code(s): |
|
EBVBAL / HCEBVBAL
|
|
|
|
|
|
|
| CPT Code(s): |
|
87798
|
|
|
|
|
|
|
| Methodology: |
|
Real-Time PCR
|
|
|
|
|
|
|
| Clinical Significance: |
|
Detect Epstein-Barr Virus (EBV) in bronchoalveolar lavage specimens.
|
|
|
|
|
|
|
| Days Performed: |
|
Mon-Fri.
|
|
|
|
|
|
|
| Turnaround Time: |
|
Stat: Not available stat.
Routine: 2 - 3 days.
|
|
|
|
Specimen Requirements
|
|
|
|
| Specimen: |
|
Bronchoalveolar lavage (BAL)
|
|
|
|
|
|
|
| Collection Instructions: |
|
10-50 mL of lavage specimen is recommended.
|
|
|
|
|
|
|
| Collection Container: |
|
Preferred: Sterile screw cap container
|
|
|
|
|
|
|
| Collection Volume: |
|
Preferred: 50 mL
Pediatrics: 12 mL
|
|
|
|
|
|
|
| Sample Analyzed: |
|
Bronchoalveolar lavage (BAL) fluid
|
|
|
|
|
|
|
| Volume Required: |
|
Preferred: 3 mL
Pediatrics: 1.2 mL
|
|
|
|
|
|
|
| Specimen Processing: |
|
None
|
|
|
|
|
|
|
| Specimen Transport: |
|
Transport specimen to UWHC Core Laboratory (B4/220) immediately. Transport fluid on coolant pack.
|
|
|
|
|
|
|
| Unacceptable Criteria: |
|
LIMIT: One specimen every 48 hours.
|
|
|
|
|
|
|
| Stability: |
|
Ambient: 3 days
Refrigerated: 3 days
Frozen: 30 days
|
|
|
|
Interpretation
|
|
|
|
|
Expected Results:
|
|
Not detected
Detection of low levels of EBV in specimens containing leukocytes is not unexpected, due to the ubiquitous nature of EBV infection in the population.
|
|
|
|
|
|
|
| Additional Information: |
|
False negative results may be due to the suppression of viral replication to levels below the detection threshold, insufficient specimen collection volumes, high dilution volumes, or to inhibitory substances that may be present in the specimen. Inadequate specimen collection, processing and storage may invalidate test results. This test should not be used as the only criterion to form a clinical conclusion, instead, results should be correlated with other test results, patient symptoms and clinical presentation. DNA sequence polymorphisms in EBV strains may results in underestimation of viral levels. The presence of variations in EBV DNA sequences are monitored in the real-time PCR assay. This assay does not genotype the virus, and consequently does not provide any information with regard to EBV drug resistance.
The performance characteristics of this test were validated by UWHC Clinical Laboratories. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test; however, FDA approval or clearance is currently not required for clinical use of this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. The UWHC Clinical Laboratories is authorized under Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing.
|
